Rapport Therapeutics

Company snapshot

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Rapport Therapeutics. Not investment advice.

• Peer + 0 momentum

  Xenon Pharmaceuticals

  TA overlap score 34.4

• Peer + 0 momentum

  SUPERNUS PHARMACEUTICALS

  TA overlap score 31

Recent activity

Latest pipeline, patent, and corporate events for Rapport Therapeutics.

1. Jun 8, 2026 Clinical update

   RAP-219-103 — Phase 1

2. May 23, 2026 Clinical update

   RAP-219 — Phase 3

3. May 23, 2026 Clinical update

   RAP-219 — Phase 2

4. May 23, 2026 Clinical update

   RAP-219 — Phase 2

5. May 23, 2026 Clinical update

   RAP-219 — Phase 2

View all clinical trial activity →

• What is Rapport Therapeutics?

  Rapport Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker RAPP. Primary therapeutic focus areas include Epilepsy, Bipolar 1 Disorder, Focal Epilepsy, Focal Onset Seizures, Focal Seizure. NovaPharmaNews links 5 clinical program(s),

• Is Rapport Therapeutics publicly traded?

  Yes. Rapport Therapeutics is listed with ticker RAPP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Rapport Therapeutics develop or market?

  We link 1 drug profile(s) where Rapport Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/rapport-therapeutics#company-drugs.

• What are the latest developments for Rapport Therapeutics?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Rapport Therapeutics focus on?

  Rapport Therapeutics focuses on Epilepsy, Bipolar 1 Disorder, Focal Epilepsy based on our analysis of their pipeline programs and drug development activities.